666_老虎社区_美港股上老虎

2021-12-27

666

Teladoc Stock: Is Cathie Wood’s Meme Stock a Buy?

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":696909049,"tweetId":"696909049","gmtCreate":1640588287411,"gmtModify":1640588287721,"author":{"id":3581742924827239,"idStr":"3581742924827239","authorId":3581742924827239,"authorIdStr":"3581742924827239","name":"JiaocyTi","avatar":"https://static.tigerbbs.com/c16d760078e396b46033bc97afede0c8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":24,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>666</body></html>","htmlText":"<html><head></head><body>666</body></html>","text":"666","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/696909049","repostId":1170511361,"repostType":4,"repost":{"id":"1170511361","kind":"news","pubTimestamp":1640587121,"share":"https://www.laohu8.com/m/news/1170511361?lang=&edition=full","pubTime":"2021-12-27 14:38","market":"us","language":"en","title":"Teladoc Stock: Is Cathie Wood’s Meme Stock a Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=1170511361","media":"TheStreet","summary":"Teladoc has arguably reached “meme” status. But this Cathie Wood-backed telemedicine company is near","content":"Teladoc has arguably reached “meme” status. But this Cathie Wood-backed telemedicine company is nearly 70% off its all-time highs from earlier this year.\nThe largest telehealth provider company in the world, Teladoc&nbsp;has been looking quite meme-y as of late. Its popularity on major discussion forums has risen; there’s increased short interest following its poor trading performance through the latter half of this year;andTDOC shares are one of the main holdings of the recently launched MEME ETF.\n<img src=\"https://static.tigerbbs.com/1d7ade96a142c2c31535c4c05941b745\" tg-width=\"1240\" tg-height=\"930\" width=\"100%\" height=\"auto\">Figure 1: Teladoc offices.\nTeladoc stock has also drawn investors’ attention because the company is one of the largest positions in Cathie Wood’s ARK Invest ETF family. The company was chosen for its disruptive business model, which fits right in with Ms. Wood’s investment strategy.\nHere, we’ll take a closer look at Cathie Wood's “meme stock” bet. This is what you should know about TDOC shares.\nCathie Wood is buying the dip\nCathie Wood’s bullishness on Teladoc stock is undeniable. The telemedicine company is thelargestholding, by percentage, in the ARK Genomic Revolution ETF&nbsp;(ARKG), accounting for 7% of the fund. It’s also thethird-largestholding on the ARK Innovation ETF&nbsp;(ARKK), accounting for 6.5% of the fund and sitting below only Tesla&nbsp;(TSLA)&nbsp;and Roku&nbsp;(ROKU)&nbsp;in weight share.\nIn all of Ark Invest’s ETFs combined, Teladoc stock is the second-largest holding. In fact, Ark Invest owns nearly 11% of all TDOC shares, with shares having been bought at prices ranging from $148 to $172.\nCathie Wood&nbsp;started&nbsp;investing in Teladoc in September of 2020, right in the middle of the COVID-19 pandemic. Early this year, Wood&nbsp;mentioned&nbsp;that her bullishness on Teladoc is due to her optimism about telemedicine innovations driven by artificial intelligence (AI). She expects the AI market to potentially reach $30 trillion over the next ten years. Following Teledoc’s&nbsp;acquisition of Livongo, Mrs. Wood believes Teladoc stands to be a clear beneficiary of AI market trends.\nWhen asked about the prospect of Teladoc and other pandemic stay-at-home plays in a post-pandemic world, Mrs. Wood reiterated her belief that COVID-19 has only accelerated ongoing innovation processes, which will continue whether or not the pandemic peters out.\nMrs. Wood made these statements in late February 2021. Since then, TDOC stock has dropped nearly 65% — yet Wood has continued to buy dips even into early December this year.\nSee the chart below:\n<img src=\"https://static.tigerbbs.com/688b2b77400231262232209461b60052\" tg-width=\"1212\" tg-height=\"632\" width=\"100%\" height=\"auto\">Figure 2: ARKK holdings of Teladoc Health.\nWhy is TDOC a meme stock?\nThe recently launched MEME ETF bases its methodology for selecting “meme stocks” on factors including a “social media activity score” (which itself is based on the number of social media mentions) and a short interest-based ranking. Holdings are then adjusted every two weeks based on updated calculations.\nTeladoc sits at the third position, by weight, on the MEME ETF holdings list (see below).\n<img src=\"https://static.tigerbbs.com/709d088c2501963d4a67373794a1b597\" tg-width=\"898\" tg-height=\"559\" width=\"100%\" height=\"auto\">Figure 3: MEME ETF holdings.\nA sizable&nbsp;14% of TDOC’s float&nbsp;is currently shorted. Bearishness surrounding the stock’s poor trading performance and weak outlooks for a post-pandemic scenario may have worked to drive both TDOC’s short interestandits popularity on main discussion forums.\nWall Street sees TDOC as undervalued\nAnalysts’&nbsp;consensus&nbsp;on TDOC shares currently suggests the stock is a “moderate buy.” Its average price target, $159, implies a 67% upside ahead – that’s based on the last three months of analysis provided by 22 Wall Street experts.\nBulls, like Credit Suisse’s Jailendra Singh, forecast more than 115% upside potential ahead for Teladoc stock. His buy rating is based on Teladoc outperforming its peers. But he also&nbsp;mentioned&nbsp;that downside risks such as loss of any major contracts and failure to improve revenue and margins from current members may impact his bullish share price target, which he&nbsp;lowered&nbsp;by a dollar a month ago to $207.\nAt the same time, even a more skeptical analyst, like Jefferies analyst Glen Santagelo, who put out a&nbsp;neutral&nbsp;rating on TDOC shares, sees 18% upside ahead. Santagelo is concerned about multiple upcoming expansions, as revenue deceleration and investments’ impact on margins for FY 2022 may have compromised some of TDOC’s acquisition power. Nevertheless, the analyst remains “cautiously optimistic” on their outlook for Primary360, a key service that allows members to choose a primary care provider and work with a care team.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teladoc Stock: Is Cathie Wood’s Meme Stock a Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeladoc Stock: Is Cathie Wood’s Meme Stock a Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 14:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/teladoc-stock-is-cathie-woods-meme-stock-a-buy>TheStreet</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nTeladoc has arguably reached “meme” status. But this Cathie Wood-backed telemedicine company is nearly 70% off its all-time highs from earlier this year.\nThe largest telehealth provider company in the...\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/teladoc-stock-is-cathie-woods-meme-stock-a-buy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/teladoc-stock-is-cathie-woods-meme-stock-a-buy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170511361","content_text":"Teladoc has arguably reached “meme” status. But this Cathie Wood-backed telemedicine company is nearly 70% off its all-time highs from earlier this year.\nThe largest telehealth provider company in the world, Teladoc has been looking quite meme-y as of late. Its popularity on major discussion forums has risen; there’s increased short interest following its poor trading performance through the latter half of this year;andTDOC shares are one of the main holdings of the recently launched MEME ETF.\nFigure 1: Teladoc offices.\nTeladoc stock has also drawn investors’ attention because the company is one of the largest positions in Cathie Wood’s ARK Invest ETF family. The company was chosen for its disruptive business model, which fits right in with Ms. Wood’s investment strategy.\nHere, we’ll take a closer look at Cathie Wood's “meme stock” bet. This is what you should know about TDOC shares.\nCathie Wood is buying the dip\nCathie Wood’s bullishness on Teladoc stock is undeniable. The telemedicine company is thelargestholding, by percentage, in the ARK Genomic Revolution ETF (ARKG), accounting for 7% of the fund. It’s also thethird-largestholding on the ARK Innovation ETF (ARKK), accounting for 6.5% of the fund and sitting below only Tesla (TSLA) and Roku (ROKU) in weight share.\nIn all of Ark Invest’s ETFs combined, Teladoc stock is the second-largest holding. In fact, Ark Invest owns nearly 11% of all TDOC shares, with shares having been bought at prices ranging from $148 to $172.\nCathie Wood started investing in Teladoc in September of 2020, right in the middle of the COVID-19 pandemic. Early this year, Wood mentioned that her bullishness on Teladoc is due to her optimism about telemedicine innovations driven by artificial intelligence (AI). She expects the AI market to potentially reach $30 trillion over the next ten years. Following Teledoc’s acquisition of Livongo, Mrs. Wood believes Teladoc stands to be a clear beneficiary of AI market trends.\nWhen asked about the prospect of Teladoc and other pandemic stay-at-home plays in a post-pandemic world, Mrs. Wood reiterated her belief that COVID-19 has only accelerated ongoing innovation processes, which will continue whether or not the pandemic peters out.\nMrs. Wood made these statements in late February 2021. Since then, TDOC stock has dropped nearly 65% — yet Wood has continued to buy dips even into early December this year.\nSee the chart below:\nFigure 2: ARKK holdings of Teladoc Health.\nWhy is TDOC a meme stock?\nThe recently launched MEME ETF bases its methodology for selecting “meme stocks” on factors including a “social media activity score” (which itself is based on the number of social media mentions) and a short interest-based ranking. Holdings are then adjusted every two weeks based on updated calculations.\nTeladoc sits at the third position, by weight, on the MEME ETF holdings list (see below).\nFigure 3: MEME ETF holdings.\nA sizable 14% of TDOC’s float is currently shorted. Bearishness surrounding the stock’s poor trading performance and weak outlooks for a post-pandemic scenario may have worked to drive both TDOC’s short interestandits popularity on main discussion forums.\nWall Street sees TDOC as undervalued\nAnalysts’ consensus on TDOC shares currently suggests the stock is a “moderate buy.” Its average price target, $159, implies a 67% upside ahead – that’s based on the last three months of analysis provided by 22 Wall Street experts.\nBulls, like Credit Suisse’s Jailendra Singh, forecast more than 115% upside potential ahead for Teladoc stock. His buy rating is based on Teladoc outperforming its peers. But he also mentioned that downside risks such as loss of any major contracts and failure to improve revenue and margins from current members may impact his bullish share price target, which he lowered by a dollar a month ago to $207.\nAt the same time, even a more skeptical analyst, like Jefferies analyst Glen Santagelo, who put out a neutral rating on TDOC shares, sees 18% upside ahead. Santagelo is concerned about multiple upcoming expansions, as revenue deceleration and investments’ impact on margins for FY 2022 may have compromised some of TDOC’s acquisition power. Nevertheless, the analyst remains “cautiously optimistic” on their outlook for Primary360, a key service that allows members to choose a primary care provider and work with a care team.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1428,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/696909049"}